Skip to main content

Table 3 Association between rate of subsequent exacerbation and time-to-initiation of FF/UMEC/VI as a continuous metric

From: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

 

RR

95% CI

p-value

Overall (moderate and severe) exacerbation

1.0018

(1.0005–1.0031)

0.0080

Moderate exacerbation

1.0026

(1.0011–1.0041)

0.0010

Severe exacerbation

1.0004

(0.9982–1.0027)

0.7010

  1. FF/UMEC/VI fluticasone furoate/umeclidinium/vilanterol, RR rate ratio, CI confidence interval. p-values in bold text indicate statistical significance
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us